"Vertex's Groundbreaking Drug Targets Global Market Potential, Says Cramer"

CNBC's Jim Cramer highlights Vertex Pharmaceuticals as a company to watch, as it develops a non-opioid drug, VX-548, to treat acute pain. Vertex aims to create a new class of prescription medications that address the addictive potential of opioids. Late-stage study results for VX-548 are expected within the year. Analysts at Leerink Partners believe the investment community underappreciates the potential of VX-548, comparing it to the obesity market a few years ago. Cramer's Charitable Trust owns shares of Eli Lilly, which expects its drug Mounjaro to expand its approved uses to obesity by year-end.